China Biotech Services Holdings Limited

Symbol: 8037.HK

HKSE

0.305

HKD

Market price today

  • -2.3428

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 293.79M

    MRK Cap

  • 0.03%

    DIV Yield

China Biotech Services Holdings Limited (8037-HK) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.10%

Operating Profit Margin

-0.80%

Net Profit Margin

-0.54%

Return on Assets

-0.19%

Return on Equity

-0.20%

Return on Capital Employed

-0.36%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO:Prof. Xuanming Yang
Full-time employees:162
City:Causeway Bay
Address:Sino Plaza
IPO:2004-06-17
CIK:

China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through five segments: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, Insurance brokerage, and Others segments. It also engages in the research, development, manufacture, sale, and distribution of health related and pharmaceutical products; trading of securities; money lending business; provision of tumor immune cell therapy, immune cell storage, and health management services; and provision of coordination of healthcare providers services. In addition, the company markets and sells health supplements, slimming pills, Chinese medicines, and beauty products; trades in pharmaceutical intermediates; and offers insurance brokerage services. Further, it provides property investment and logistic services. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong.

General Outlook

When we look at how much money they make before expenses, they keep 0.100% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.796%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.535%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.186% return, is a testament to China Biotech Services Holdings Limited's adeptness in optimizing resource deployment. China Biotech Services Holdings Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.198%. Furthermore, the proficiency of China Biotech Services Holdings Limited in capital utilization is underscored by a remarkable -0.364% return on capital employed.

Stock Prices

China Biotech Services Holdings Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.49, while its low point bottomed out at $0.49. This variance in figures offers investors a lucid insight into the roller-coaster ride that is China Biotech Services Holdings Limited's stock market.

Liquidity Ratios

Analyzing 8037.HK liquidity ratios reveals its financial health of the firm. The current ratio of 163.77% gauges short-term asset coverage for liabilities. The quick ratio (154.30%) assesses immediate liquidity, while the cash ratio (129.74%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio163.77%
Quick Ratio154.30%
Cash Ratio129.74%

Profitability Ratios

8037.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -83.58% underscores its earnings before tax deductions. The effective tax rate stands at 0.91%, revealing its tax efficiency. The net income per EBT, 64.07%, and the EBT per EBIT, 105.05%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -79.57%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-83.58%
Effective Tax Rate0.91%
Net Income per EBT64.07%
EBT per EBIT105.05%
EBIT per Revenue-79.57%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.64, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 588.10% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding154
Days of Inventory Outstanding16
Operating Cycle78.38
Days of Payables Outstanding10
Cash Conversion Cycle68
Receivables Turnover5.88
Payables Turnover35.84
Inventory Turnover22.37
Fixed Asset Turnover1.85
Asset Turnover0.35

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.20, and free cash flow per share, 0.20, depict cash generation on a per-share basis. The cash per share value, 0.21, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.84, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.20
Free Cash Flow per Share0.20
Cash per Share0.21
Operating Cash Flow Sales Ratio0.84
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio1.92
Short Term Coverage Ratio2.03

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 15.16%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.22, we discern the balance between debt and equity financing. The long-term debt to capitalization, 1.22%, and total debt to capitalization, 17.83%, ratios shed light on its capital structure. An interest coverage of -34.51 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio15.16%
Debt Equity Ratio0.22
Long Term Debt to Capitalization1.22%
Total Debt to Capitalization17.83%
Interest Coverage-34.51
Cash Flow to Debt Ratio1.92
Company Equity Multiplier1.43

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.22, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.10, reflects the portion of profit attributed to each share. The book value per share, 0.48, represents the net asset value distributed per share, while the tangible book value per share, 0.33, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.22
Net Income Per Share-0.10
Book Value Per Share0.48
Tangible Book Value Per Share0.33
Shareholders Equity Per Share0.48
Interest Debt Per Share0.11
Capex Per Share-0.07

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -88.55%, indicates top-line expansion, while the gross profit growth, -96.88%, reveals profitability trends. EBIT growth, -114.52%, and operating income growth, -114.52%, offer insights into operational profitability progression. The net income growth, -113.53%, showcases bottom-line expansion, and the EPS growth, -113.58%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-88.55%
Gross Profit Growth-96.88%
EBIT Growth-114.52%
Operating Income Growth-114.52%
Net Income Growth-113.53%
EPS Growth-113.58%
EPS Diluted Growth-113.58%
Operating Cash Flow Growth-60.11%
Free Cash Flow Growth-68.60%
10-Year Revenue Growth per Share-86.60%
5-Year Revenue Growth per Share176.01%
3-Year Revenue Growth per Share-67.50%
10-Year Operating CF Growth per Share142.71%
5-Year Operating CF Growth per Share1294.36%
3-Year Operating CF Growth per Share-54.12%
10-Year Net Income Growth per Share89.79%
5-Year Net Income Growth per Share-35.98%
3-Year Net Income Growth per Share-157.25%
10-Year Shareholders Equity Growth per Share-75.74%
5-Year Shareholders Equity Growth per Share30.71%
3-Year Shareholders Equity Growth per Share35.52%
Receivables Growth-94.90%
Inventory Growth-50.47%
Asset Growth-54.96%
Book Value per Share Growth-23.22%
Debt Growth22.76%
R&D Expense Growth4.62%
SGA Expenses Growth-49.40%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 635,187,870, captures the company's total value, considering both debt and equity. Income quality, -2.02, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.65, gauges operational efficiency, while the research and development to revenue, 13.70%, highlights investment in innovation. The ratio of intangibles to total assets, 26.72%, indicates the value of non-physical assets, and capex to operating cash flow, -32.65%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value635,187,870
Income Quality-2.02
Sales General and Administrative to Revenue0.65
Research and Development to Revenue13.70%
Intangibles to Total Assets26.72%
Capex to Operating Cash Flow-32.65%
Capex to Revenue-29.66%
Capex to Depreciation-113.14%
Stock-Based Compensation to Revenue0.89%
Graham Number1.03
Return on Tangible Assets-19.66%
Graham Net Net0.07
Working Capital101,699,000
Tangible Asset Value313,733,000
Net Current Asset Value89,530,000
Average Receivables403,839,500
Average Payables106,114,000
Average Inventory13,999,500
Days Sales Outstanding67
Days Payables Outstanding12
Days of Inventory On Hand19
ROIC-21.75%
ROE-0.21%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.62, and the price to book ratio, 0.62, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.25, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 1.50, and price to operating cash flows, 1.50, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.62
Price to Book Ratio0.62
Price to Sales Ratio1.25
Price Cash Flow Ratio1.50
Enterprise Value Multiple-2.33
Price Fair Value0.62
Price to Operating Cash Flow Ratio1.50
Price to Free Cash Flows Ratio1.50
Price to Tangible Book Ratio1.60
Enterprise Value to Sales3.00
Enterprise Value Over EBITDA-9.33
EV to Operating Cash Flow3.30
Earnings Yield-12.87%
Free Cash Flow Yield17.49%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of China Biotech Services Holdings Limited (8037.HK) on the HKSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -2.343 in 2024.

What is the ticker symbol of China Biotech Services Holdings Limited stock?

The ticker symbol of China Biotech Services Holdings Limited stock is 8037.HK.

What is company IPO date?

IPO date of China Biotech Services Holdings Limited is 2004-06-17.

What is company current share price?

Current share price is 0.305 HKD.

What is stock market cap today?

The market cap of stock today is 293785455.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 162.